Protalix BioTherapeutics, Inc. (PLX) 8-K Current Report: March 9, 2026
Filed: March 9, 2026
Health Care
Biological Products, (No Diagnostic Substances)Protalix BioTherapeutics, Inc. (PLX) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Protalix BioTherapeutics, Inc. 8-K Mar 9, 2026 Event Analysis
Item 8.01 · Other Events
- • EC approved new E4W (every-4-weeks) 2 mg/kg dosing regimen for Elfabrio in EU — expands label beyond prior dosing schedule
- • Label expansion targets stable Fabry disease patients on ERT, potentially broadening addressable patient pool and improving convenience vs. more frequent dosing
- • Approval follows positive CHMP opinion from EMA — regulatory pathway was de-risked before EC decision
- • Commercial partner Chiesi Global Rare Diseases handles EU commercialization, meaning PLX benefits via royalties/milestones rather than direct sales
Other Protalix BioTherapeutics, Inc. 8-K Filings
Get deeper insights on Protalix BioTherapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.